Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets

Paul J.W.H. Kappelle; Geesje M. Dallinga-Thie; Robin P. F. Dullaart; Diabet Atorvastatin Lipid Interven

doi:10.1016/j.bbalip.2009.09.021

Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets

Paul J.W.H. Kappelle
, Geesje M. Dallinga-Thie
, Robin P. F. Dullaart^*
, Diabet Atorvastatin Lipid Interven

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

21 Citations (Scopus)

Abstract

The extent to which atorvastatin treatment affects LDL size, LDL subfraction levels and remnant-like particle cholesterol (RLP-C) was determined in type 2 diabetes. We also compared LDL size and RLP-C in relation to guideline cut-off values for LDL cholesterol, non-HDL cholesterol and apolipoprotein (apo) B. Changes in LDL size and RLP-C were determined in fasting plasma from type 2 diabetic patients after 30 weeks administration of atorvastatin (10 mg daily, n=65; 80 mg daily, n=62) or placebo (n=58). LDL subfraction cholesterol was measured in 74 participants. Atorvastatin lowered LDL cholesterol, non-HDL cholesterol, triglycerides, apo B and RLP-C (P

Original language	English
Pages (from-to)	89-94
Number of pages	6
Journal	Biochimica et biophysica acta-Molecular and cell biology of lipids
Volume	1801
Issue number	1
DOIs	https://doi.org/10.1016/j.bbalip.2009.09.021
Publication status	Published - Jan-2010

Keywords

Apolipoprotein B
atorvastatin
Diabetes mellitus
LDL-cholesterol
LDL subfractions
Non-HDL-cholesterol
Remnant-like particle cholesterol
Small dense LDL
Triglycerides
LOW-DENSITY-LIPOPROTEIN
CORONARY-ARTERY-DISEASE
ESTER TRANSFER PROTEIN
HIGH-RISK PATIENTS
HEART-DISEASE
FAMILIAL HYPERCHOLESTEROLEMIA
CARDIOVASCULAR MORTALITY
STATIN THERAPY
A-I
DYSLIPIDEMIA

Access to Document

10.1016/j.bbalip.2009.09.021

Handle.net

Persistent link

Fingerprint

Dive into the research topics of 'Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets'. Together they form a unique fingerprint.

Cite this

Kappelle, P. J. W. H., Dallinga-Thie, G. M., Dullaart, R. P. F., & Diabet Atorvastatin Lipid Interven (2010). Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets. Biochimica et biophysica acta-Molecular and cell biology of lipids, 1801(1), 89-94. https://doi.org/10.1016/j.bbalip.2009.09.021

Kappelle, Paul J.W.H. ; Dallinga-Thie, Geesje M. ; Dullaart, Robin P. F. et al. / Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus : Relevance for non-HDL cholesterol and apolipoprotein B guideline targets. In: Biochimica et biophysica acta-Molecular and cell biology of lipids. 2010 ; Vol. 1801, No. 1. pp. 89-94.

@article{fadddc38ee784d5ba7997d364492be2f,

title = "Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets",

abstract = "The extent to which atorvastatin treatment affects LDL size, LDL subfraction levels and remnant-like particle cholesterol (RLP-C) was determined in type 2 diabetes. We also compared LDL size and RLP-C in relation to guideline cut-off values for LDL cholesterol, non-HDL cholesterol and apolipoprotein (apo) B. Changes in LDL size and RLP-C were determined in fasting plasma from type 2 diabetic patients after 30 weeks administration of atorvastatin (10 mg daily, n=65; 80 mg daily, n=62) or placebo (n=58). LDL subfraction cholesterol was measured in 74 participants. Atorvastatin lowered LDL cholesterol, non-HDL cholesterol, triglycerides, apo B and RLP-C (P",

keywords = "Apolipoprotein B, atorvastatin, Diabetes mellitus, LDL-cholesterol, LDL subfractions, Non-HDL-cholesterol, Remnant-like particle cholesterol, Small dense LDL, Triglycerides, LOW-DENSITY-LIPOPROTEIN, CORONARY-ARTERY-DISEASE, ESTER TRANSFER PROTEIN, HIGH-RISK PATIENTS, HEART-DISEASE, FAMILIAL HYPERCHOLESTEROLEMIA, CARDIOVASCULAR MORTALITY, STATIN THERAPY, A-I, DYSLIPIDEMIA",

author = "Kappelle, \{Paul J.W.H.\} and Dallinga-Thie, \{Geesje M.\} and Dullaart, \{Robin P. F.\} and \{Diabet Atorvastatin Lipid Interven\}",

year = "2010",

month = jan,

doi = "10.1016/j.bbalip.2009.09.021",

language = "English",

volume = "1801",

pages = "89--94",

journal = "Biochimica et biophysica acta-Molecular and cell biology of lipids",

issn = "1388-1981",

publisher = "Elsevier",

number = "1",

}

Kappelle, PJWH, Dallinga-Thie, GM, Dullaart, RPF & Diabet Atorvastatin Lipid Interven 2010, 'Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets', Biochimica et biophysica acta-Molecular and cell biology of lipids, vol. 1801, no. 1, pp. 89-94. https://doi.org/10.1016/j.bbalip.2009.09.021

Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets. / Kappelle, Paul J.W.H.; Dallinga-Thie, Geesje M.; Dullaart, Robin P. F. et al.
In: Biochimica et biophysica acta-Molecular and cell biology of lipids, Vol. 1801, No. 1, 01.2010, p. 89-94.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus

T2 - Relevance for non-HDL cholesterol and apolipoprotein B guideline targets

AU - Kappelle, Paul J.W.H.

AU - Dallinga-Thie, Geesje M.

AU - Dullaart, Robin P. F.

AU - Diabet Atorvastatin Lipid Interven

PY - 2010/1

Y1 - 2010/1

N2 - The extent to which atorvastatin treatment affects LDL size, LDL subfraction levels and remnant-like particle cholesterol (RLP-C) was determined in type 2 diabetes. We also compared LDL size and RLP-C in relation to guideline cut-off values for LDL cholesterol, non-HDL cholesterol and apolipoprotein (apo) B. Changes in LDL size and RLP-C were determined in fasting plasma from type 2 diabetic patients after 30 weeks administration of atorvastatin (10 mg daily, n=65; 80 mg daily, n=62) or placebo (n=58). LDL subfraction cholesterol was measured in 74 participants. Atorvastatin lowered LDL cholesterol, non-HDL cholesterol, triglycerides, apo B and RLP-C (P

AB - The extent to which atorvastatin treatment affects LDL size, LDL subfraction levels and remnant-like particle cholesterol (RLP-C) was determined in type 2 diabetes. We also compared LDL size and RLP-C in relation to guideline cut-off values for LDL cholesterol, non-HDL cholesterol and apolipoprotein (apo) B. Changes in LDL size and RLP-C were determined in fasting plasma from type 2 diabetic patients after 30 weeks administration of atorvastatin (10 mg daily, n=65; 80 mg daily, n=62) or placebo (n=58). LDL subfraction cholesterol was measured in 74 participants. Atorvastatin lowered LDL cholesterol, non-HDL cholesterol, triglycerides, apo B and RLP-C (P

KW - Apolipoprotein B

KW - atorvastatin

KW - Diabetes mellitus

KW - LDL-cholesterol

KW - LDL subfractions

KW - Non-HDL-cholesterol

KW - Remnant-like particle cholesterol

KW - Small dense LDL

KW - Triglycerides

KW - LOW-DENSITY-LIPOPROTEIN

KW - CORONARY-ARTERY-DISEASE

KW - ESTER TRANSFER PROTEIN

KW - HIGH-RISK PATIENTS

KW - HEART-DISEASE

KW - FAMILIAL HYPERCHOLESTEROLEMIA

KW - CARDIOVASCULAR MORTALITY

KW - STATIN THERAPY

KW - A-I

KW - DYSLIPIDEMIA

U2 - 10.1016/j.bbalip.2009.09.021

DO - 10.1016/j.bbalip.2009.09.021

M3 - Article

SN - 1388-1981

VL - 1801

SP - 89

EP - 94

JO - Biochimica et biophysica acta-Molecular and cell biology of lipids

JF - Biochimica et biophysica acta-Molecular and cell biology of lipids

IS - 1

ER -

Kappelle PJWH, Dallinga-Thie GM, Dullaart RPF, Diabet Atorvastatin Lipid Interven. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets. Biochimica et biophysica acta-Molecular and cell biology of lipids. 2010 Jan;1801(1):89-94. doi: 10.1016/j.bbalip.2009.09.021